Nuveen’s CytomX Therapeutics CTMX Stock Holding History

Nuveen’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68M	Buy	+448,041	New	+$1.71M	﹤0.01%	2671
2022 Q2	–	Sell	-200,943	Closed	-$621K	–	3295
2022 Q1	$621K	Buy	200,943 +1,413	+0.7%	+$5.43K	﹤0.01%	2950
2021 Q4	$1.23M	Sell	199,530 -23,936	-11%	-$140K	﹤0.01%	2782
2021 Q3	$1.17M	Buy	223,466 +32,365	+17%	+$173K	﹤0.01%	2933
2021 Q2	$1.21M	Sell	191,101 -373,466	-66%	-$2.91M	﹤0.01%	2941
2021 Q1	$4.37M	Sell	564,567 -45,829	-8%	-$363K	﹤0.01%	2227
2020 Q4	$4M	Sell	610,396 -20,523	-3%	-$147K	﹤0.01%	2184
2020 Q3	$4.2M	Sell	630,919 -92,882	-13%	-$689K	﹤0.01%	2014
2020 Q2	$6.03M	Buy	723,801 +2,833	+0.4%	+$26.3K	﹤0.01%	1797
2020 Q1	$5.53M	Buy	720,968 +18,660	+3%	+$130K	﹤0.01%	1652
2019 Q4	$5.84M	Sell	702,308 -41,278	-6%	-$279K	﹤0.01%	1903
2019 Q3	$5.49M	Sell	743,586 -814	-0.1%	-$8.03K	﹤0.01%	1902
2019 Q2	$8.35M	Buy	+744,400	New	+$7.8M	﹤0.01%	1717

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Nuveen's CTMX Position: Q2 2026 in Review

Nuveen opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 448,041 shares worth $1.68M. The stake represents ﹤0.01% of the portfolio and ranks #2671 among its holdings. This is a return to the name: Nuveen previously reported a position in CTMX as recently as Q1 2022.

Nuveen first reported a position in CTMX in Q2 2019 and has held it in 13 quarters since. The position peaked at $8.35M in Q2 2019. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Nuveen held 448,041 shares of CytomX Therapeutics worth $1.68M as of Q2 2026.
CytomX Therapeutics was a new Nuveen position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2671 holding.
Nuveen first reported a position in CytomX Therapeutics in Q2 2019 and has held it in 13 quarters since.
Nuveen's CytomX Therapeutics position peaked at $8.35M in Q2 2019.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.